Compared with standard tyrosine kinase inhibitors, asciminib demonstrated improved safety and tolerability for the treatment of chronic myeloid leukemia, according to phase 3 data presented at the 66th ASH annual meeting.
Compared with standard tyrosine kinase inhibitors, asciminib demonstrated improved safety and tolerability for the treatment of chronic myeloid leukemia, according to phase 3 data presented at the 66th ASH annual meeting.
Compared with standard tyrosine...